A Phase 1B Study of Donafenib Monotherapy in Advanced Oesophageal Cancer Progressing After Chemotherapy
Phase of Trial: Phase I/II
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Donafenib (Primary)
- Indications Oesophageal cancer
- Focus Adverse reactions
- Sponsors Suzhou Zelgen Biopharmaceuticals
- 10 Oct 2017 Planned End Date changed from 1 Oct 2017 to 1 Aug 2019.
- 10 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Jun 2018.
- 12 Aug 2016 Status changed from active, no longer recruiting to recruiting.